Moreover, given c-MET’s diverse tumorigenic functions and its pivotal role in the invasiveness of aggressive tumors like NSCLC, the advent of c-MET-specific CAR-immune cells kindles hope for treating patients grappling with malignant tumors through more precisely tailored immunotherapeutic strategies targeting the formidable c-MET receptor. Here, MET is linked to non-small cell lung carcinoma.